Insight

The potential of precision medicine in gynaecologic cancers – ESMO

Photo from ESMO/LinkedIn

Jun 25, 2024, 03:43

The potential of precision medicine in gynaecologic cancers – ESMO

The European Society for Medical Oncology (ESMO) shared on LinkedIn:

“ESMOGynae24: The combination of comprehensive genomic profiling and ranking genomic alterations using the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

After discussion in a Molecular Tumour Board, 22 patients received molecularly guided treatment options showcasing the potential of precision medicine in gynaecologic cancers, where ESMO is showing its commitment to facilitating patients’ access to optimal cancer care.”

Source: ESMO/LinkedIn

cancer ESCAT ESMO ESMO Scale for Clinical Actionability of molecular Targets ESMOGynae24 European Society for Medical Oncology gynaecologic cancers Molecular Tumour Board OncoDaily Oncology Precision Medicine

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Dennis Slamon was honored with the 2024 Szent-Györgyi Prize for Progress in Cancer Research

Pfizer is partnering with Patrick Dempsey in support of the American Cancer Society initiative 'Change the Odds'

Special Coverage